FMP
NASDAQ
0.36 USD
-0.0139 (-3.85%)
Dr. Charles P. Theuer M.D., Ph.D.
Healthcare
Biotechnology
https://www.traconpharma.com
NASDAQ
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I...
0001394319
US89237H2094
89237H209
4350 La Jolla Village Drive
858 550 0780
US
17
Jan 30, 2015
0001394319
NASDAQ
Biotechnology
Healthcare
89237H209
US89237H2094
US
0.36
0.79
3.08M
16.43M
-
0.126-2.19
0.36
-
-
-
-
-3.28
-
https://www.traconpharma.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.